Bulletin
Investor Alert

New York Markets Open in:

Lineage Cell Therapeutics Inc.

ASE: LCTX

GO
/marketstate/country/us

After Hours

/zigman2/quotes/207994235/composite

$

2.55

Change

-0.04 -1.54%

Volume

Volume 5,152

Jan 25, 2021, 7:26 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/207994235/composite

Previous close

$ 2.66

$ 2.59

Change

-0.07 -2.63%

Day low

Day high

$2.22

$2.70

Open
Open: 2.61

52 week low

52 week high

$0.58

$3.03

Open

Market cap

$398.98M

Average volume

1.61M

P/E ratio

N/A

Rev. per Employee

$26,873

EPS

-0.18

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/lctx

MarketWatch News on LCTX

  1. BioTime started at buy with $3 stock price target at Maxim Group

    7:46 a.m. Jan. 24, 2019

    - Tomi Kilgore

  2. BioTime started at outperform with $6 stock price target at Raymond James

    7:15 a.m. March 31, 2017

    - Tomi Kilgore

  3. 13D Filings

    11:38 p.m. June 27, 2014

    - Barron's Online

  4. 13D Filings

    1:49 a.m. May 10, 2014

    - Barron's Online

  5. 13D Filings

    2:32 a.m. Jan. 4, 2014

    - Barron's Online

  6. BioTime offers equity stake for Geron assets

    8:46 a.m. Oct. 18, 2012

    - MarketWatch.com

  7. Osiris stem-cell therapy wins Canadian approval

    4:42 p.m. May 17, 2012

    - Val Brickates Kennedy

  8. Court upholds stem-cell research funding: reports

    10:45 a.m. July 27, 2011

    - Val Brickates Kennedy

  9. Are stem-cell stocks a good buy?

    2:05 p.m. July 13, 2011

    - Val Brickates Kennedy

  10. Endo, Celgene lead drug stocks lower

    3:53 p.m. Dec. 8, 2009

    - Val Brickates Kennedy

  11. BioTime Q2 revs $195,337 vs $97,297

    6:12 a.m. Aug. 13, 2004

    - Robert Daniel

  12. BioTime Q2 losses 2c vs 6c

    6:11 a.m. Aug. 13, 2004

    - Robert Daniel

  13. 13D Filings

    11:59 p.m. Feb. 23, 2004

    - Barron's Online

  14. BioTime plans rights offering

    8:15 a.m. Oct. 2, 2003

    - Greg Morcroft

  15. 13D Filings

    11:01 p.m. June 9, 2002

    - Barron's Online

  16. Winners and Sinners

    6:03 p.m. Oct. 20, 1997

    - Barron's Online

Analyst Ratings

/news/nonmarketwatch/company/us/lctx

Other News on LCTX

  1. Lineage Cell announces changes in executive team; shares up 7%

    7:19 a.m. Jan. 21, 2021

    - Seeking Alpha

  2. NFLX, TELL, CLBS, and FUTU among notable pre-market gainers

    8:23 a.m. Jan. 20, 2021

    - Seeking Alpha

  3. Maxim Group Keeps a Buy Rating on Lineage Cell Therapeutics (LCTX)

    12:55 p.m. Nov. 17, 2020

    - SmarterAnalyst

  4. 10-Q: LINEAGE CELL THERAPEUTICS, INC.

    4:23 p.m. Nov. 4, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  5. Loading more headlines...
/news/pressrelease/company/us/lctx

Press Releases on LCTX

  1. Lineage Cell Therapeutics Announces Change to Executive Team

    4:18 p.m. Jan. 20, 2021

    - BusinessWire - BZX

  2. Lineage Cell Therapeutics Provides End of Year Shareholder Letter

    8:00 a.m. Dec. 28, 2020

    - BusinessWire - BZX

  3. Loading more headlines...

Rates »

Link to MarketWatch's Slice.